|Chemical and physical data|
|Molar mass||g·mol−1 339.439|
|3D model (JSmol)|
|(what is this?)|
WAY-317538 (SEN-12333) is a drug that acts as a potent and selective full agonist for the α7 subtype of neural nicotinic acetylcholine receptors. It was not the most potent compound in the series, but was selected for further development on the basis of its high selectivity over related receptors, ease of synthesis, and good in vivo properties including high oral bioavailability and good brain penetration. It has nootropic and neuroprotective effects in animal studies, and is being investigated as a potential treatment for neurodegenerative and neurocognitive conditions including Alzheimer’s disease and schizophrenia.
- Haydar, S.; Ghiron, C.; Bettinetti, L.; Bothmann, H.; Comery, T.; Dunlop, J.; La Rosa, S.; Micco, I.; Pollastrini, M.; Quinn, J.; Roncarati, R.; Scali, C.; Valacchi, M.; Varrone, M.; Zanaletti, R. (2009). “SAR and biological evaluation of SEN12333/WAY-317538: Novel alpha 7 nicotinic acetylcholine receptor agonist”. Bioorganic & Medicinal Chemistry. 17 (14): 5247–5258. doi:10.1016/j.bmc.2009.05.040. PMID 19515567.
- Roncarati, R.; Scali, C.; Comery, T.; Grauer, S.; Aschmi, S.; Bothmann, H.; Jow, B.; Kowal, D.; Gianfriddo, M.; Kelley, C.; Zanelli, U.; Ghiron, C.; Haydar, S.; Dunlop, J.; Terstappen, G. C. (2009). “Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders”. The Journal of Pharmacology and Experimental Therapeutics. 329 (2): 459–468. doi:10.1124/jpet.108.150094. PMID 19223665.